195 related articles for article (PubMed ID: 36381271)
1. Multiple-low-dose therapy: effective killing of high-grade serous ovarian cancer cells with ATR and CHK1 inhibitors.
Golder A; Nelson L; Tighe A; Barnes B; Coulson-Gilmer C; Morgan RD; McGrail JC; Taylor SS
NAR Cancer; 2022 Dec; 4(4):zcac036. PubMed ID: 36381271
[TBL] [Abstract][Full Text] [Related]
2. Replication catastrophe is responsible for intrinsic PAR glycohydrolase inhibitor-sensitivity in patient-derived ovarian cancer models.
Coulson-Gilmer C; Morgan RD; Nelson L; Barnes BM; Tighe A; Wardenaar R; Spierings DCJ; Schlecht H; Burghel GJ; Foijer F; Desai S; McGrail JC; Taylor SS
J Exp Clin Cancer Res; 2021 Oct; 40(1):323. PubMed ID: 34656146
[TBL] [Abstract][Full Text] [Related]
3. Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in
Kim H; George E; Ragland R; Rafail S; Zhang R; Krepler C; Morgan M; Herlyn M; Brown E; Simpkins F
Clin Cancer Res; 2017 Jun; 23(12):3097-3108. PubMed ID: 27993965
[No Abstract] [Full Text] [Related]
4. Targeting the PI3K/mTOR Pathway Augments CHK1 Inhibitor-Induced Replication Stress and Antitumor Activity in High-Grade Serous Ovarian Cancer.
Huang TT; Brill E; Nair JR; Zhang X; Wilson KM; Chen L; Thomas CJ; Lee JM
Cancer Res; 2020 Dec; 80(23):5380-5392. PubMed ID: 32998994
[TBL] [Abstract][Full Text] [Related]
5. Exploiting a living biobank to delineate mechanisms underlying disease-specific chromosome instability.
Nelson L; Barnes BM; Tighe A; Littler S; Coulson-Gilmer C; Golder A; Desai S; Morgan RD; McGrail JC; Taylor SS
Chromosome Res; 2023 Aug; 31(3):21. PubMed ID: 37592171
[TBL] [Abstract][Full Text] [Related]
6. Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer.
Nair J; Huang TT; Murai J; Haynes B; Steeg PS; Pommier Y; Lee JM
Oncogene; 2020 Aug; 39(33):5520-5535. PubMed ID: 32647134
[TBL] [Abstract][Full Text] [Related]
7. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723
[TBL] [Abstract][Full Text] [Related]
8. The Influence of PARP, ATR, CHK1 Inhibitors on Premature Mitotic Entry and Genomic Instability in High-Grade Serous
Gralewska P; Gajek A; Rybaczek D; Marczak A; Rogalska A
Cells; 2022 Jun; 11(12):. PubMed ID: 35741017
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity of cells to ATR and CHK1 inhibitors requires hyperactivation of CDK2 rather than endogenous replication stress or ATM dysfunction.
Ditano JP; Donahue KL; Tafe LJ; McCleery CF; Eastman A
Sci Rep; 2021 Mar; 11(1):7077. PubMed ID: 33782497
[TBL] [Abstract][Full Text] [Related]
10. Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant
Burgess BT; Anderson AM; McCorkle JR; Wu J; Ueland FR; Kolesar JM
Diagnostics (Basel); 2020 Feb; 10(2):. PubMed ID: 32098452
[TBL] [Abstract][Full Text] [Related]
11. Metronomic dosing of ovarian cancer cells with the ATR inhibitor AZD6738 leads to loss of CDC25A expression and resistance to ATRi treatment.
Ao W; Kim HI; Tommarello D; Conrads KA; Hood BL; Litzi T; Abulez T; Teng PN; Dalgard CL; Zhang X; Wilkerson MD; Darcy KM; Tarney CM; Phippen NT; Bakkenist CJ; Maxwell GL; Conrads TP; Risinger JI; Bateman NW
Gynecol Oncol; 2023 Oct; 177():60-71. PubMed ID: 37639904
[TBL] [Abstract][Full Text] [Related]
12. Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions.
Alkema NG; Wisman GB; van der Zee AG; van Vugt MA; de Jong S
Drug Resist Updat; 2016 Jan; 24():55-69. PubMed ID: 26830315
[TBL] [Abstract][Full Text] [Related]
13. The disruption of the CCDC6 - PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma.
Morra F; Merolla F; Damia G; Ricci F; Varricchio S; Ilardi G; Arenare L; Califano D; Napolitano V; Fruscio R; Melillo RM; Palazzo L; Celetti A
J Exp Clin Cancer Res; 2022 Aug; 41(1):245. PubMed ID: 35964058
[TBL] [Abstract][Full Text] [Related]
14. The cytosolic iron-sulfur cluster assembly (CIA) pathway is required for replication stress tolerance of cancer cells to Chk1 and ATR inhibitors.
Redwood AB; Zhang X; Seth SB; Ge Z; Bindeman WE; Zhou X; Sinha VC; Heffernan TP; Piwnica-Worms H
NPJ Breast Cancer; 2021 Dec; 7(1):152. PubMed ID: 34857765
[TBL] [Abstract][Full Text] [Related]
15. Control of replication stress and mitosis in colorectal cancer stem cells through the interplay of PARP1, MRE11 and RAD51.
Manic G; Musella M; Corradi F; Sistigu A; Vitale S; Soliman Abdel Rehim S; Mattiello L; Malacaria E; Galassi C; Signore M; Pallocca M; Scalera S; Goeman F; De Nicola F; Guarracino A; Pennisi R; Antonangeli F; Sperati F; Baiocchi M; Biffoni M; Fanciulli M; Maugeri-Saccà M; Franchitto A; Pichierri P; De Maria R; Vitale I
Cell Death Differ; 2021 Jul; 28(7):2060-2082. PubMed ID: 33531658
[TBL] [Abstract][Full Text] [Related]
16. Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer.
Gralewska P; Gajek A; Marczak A; Rogalska A
J Hematol Oncol; 2020 Apr; 13(1):39. PubMed ID: 32316968
[TBL] [Abstract][Full Text] [Related]
17. Sequential Targeting of PLK1 and PARP1 Reverses the Resistance to PARP Inhibitors and Enhances Platin-Based Chemotherapy in BRCA-Deficient High-Grade Serous Ovarian Cancer with KRAS Amplification.
Gasimli K; Raab M; Tahmasbi Rad M; Kurunci-Csacsko E; Becker S; Strebhardt K; Sanhaji M
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142803
[TBL] [Abstract][Full Text] [Related]
18. Sensitization of Carboplatinum- and Taxol-Resistant High-Grade Serous Ovarian Cancer Cells Carrying p53, BRCA1/2 Mutations by Emblica officinalis (Amla) via Multiple Targets.
De A; De A; Sharma R; Suo W; Sharma M
J Cancer; 2020; 11(7):1927-1939. PubMed ID: 32194804
[No Abstract] [Full Text] [Related]
19. Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors.
Do KT; Kochupurakkal B; Kelland S; de Jonge A; Hedglin J; Powers A; Quinn N; Gannon C; Vuong L; Parmar K; Lazaro JB; D'Andrea AD; Shapiro GI
Clin Cancer Res; 2021 Sep; 27(17):4710-4716. PubMed ID: 34131002
[TBL] [Abstract][Full Text] [Related]
20. A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers.
George E; Kim H; Krepler C; Wenz B; Makvandi M; Tanyi JL; Brown E; Zhang R; Brafford P; Jean S; Mach RH; Lu Y; Mills GB; Herlyn M; Morgan M; Zhang X; Soslow R; Drapkin R; Johnson N; Zheng Y; Cotsarelis G; Nathanson KL; Simpkins F
JCI Insight; 2017 Jan; 2(1):e89760. PubMed ID: 28097235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
